Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses

BioFactors

Volumn 42, Issue 3, 2016, Pages 296-306

  Ribeiro, Sandra ^a   Garrido, Patrícia ^b   Fernandes, João ^b,c   Rocha Pereira, Petronila ^d   Costa, Elísio ^a   Belo, Luís ^a   Reis, Flávio ^b,c   Santos Silva, Alice ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

BMP6; chronic renal failure; erythropoietin; hepcidin; iron overload

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; HEPCIDIN; IRON; RECOMBINANT ERYTHROPOIETIN; SMAD PROTEIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ERYTHROPOIESIS; GENE EXPRESSION; INFLAMMATION; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; LIVER LEVEL; MALE; NEPHRECTOMY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; UPREGULATION; WESTERN BLOTTING;

EID: 84979208532     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1275     Document Type: Article

References (40)

1. Anderson, G. J., Frazer, D. M., and McLaren, G. D. (2009) Iron absorption and metabolism. Curr. Opin. Gastroenterol. 25, 129–135.
2. Munoz, M., Villar, I., and Garcia-Erce, J. A. (2009) An update on iron physiology. World J. Gastroenterol. 15, 4617–4626.
3. Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090–2093.
4. Zhang, A. S. (2010) Control of systemic iron homeostasis by the hemojuvelin-hepcidin axis. Adv. Nutr. 1, 38–45.
5. Kautz, L., Meynard, D., Monnier, A., Darnaud, V., Bouvet, R., et al. (2008) Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 112, 1503–1509.
6. Silvestri, L., Pagani, A., Nai, A., De Domenico, I., Kaplan, J., et al. (2008) The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 8, 502–511.
7. Corradini, E., Meynard, D., Wu, Q., Chen, S., Ventura, P., et al. (2011) Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology 54, 273–284.
8. Poli, M., Luscieti, S., Gandini, V., Maccarinelli, F., Finazzi, D., et al. (2010) Transferrin receptor 2 and HFE regulate furin expression via mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/Erk) signaling. Implications for transferrin-dependent hepcidin regulation. Haematologica 95, 1832–1840.
9. Wrighting, D. M. and Andrews, N. C. (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108, 3204–3209.
10. Pinto, J. P., Ribeiro, S., Pontes, H., Thowfeequ, S., Tosh, D., et al. (2008) Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 111, 5727–5733.
11. Peyssonnaux, C., Zinkernagel, A. S., Schuepbach, R. A., Rankin, E., Vaulont, S., et al. (2007) Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Invest. 117, 1926–1932.
12. Ganz, T. and Nemeth, E. (2012) Hepcidin and iron homeostasis. Biochim. Biophys. Acta 1823, 1434–1443.
13. Liu, Q., Davidoff, O., Niss, K., and Haase, V. H. (2012) Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J. Clin. Invest. 122, 4635–4644.
14. Ravasi, G., Pelucchi, S., Greni, F., Mariani, R., Giuliano, A., et al. (2014) Circulating factors are involved in hypoxia-induced hepcidin suppression. Blood Cells Mol. Dis. 53, 204–210.
15. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2, 279–335.
16. KDOQI & National Kidney Foundation. (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. 47, S11–S145.
17. Costa, E., Rocha, S., Rocha-Pereira, P., Nascimento, H., Castro, E., et al. (2008) Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Am. J. Nephrol. 28, 935–940.
18. do Sameiro-Faria, M., Ribeiro, S., Costa, E., Mendonca, D., Teixeira, L., et al. (2013) Risk factors for mortality in hemodialysis patients: two-year follow-up study. Dis. Markers 35, 791–798.
19. Costa, E., Swinkels, D. W., Laarakkers, C. M., Rocha-Pereira, P., Rocha, S., et al. (2009) Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol. 122, 226–229.
20. Mercadel, L., Metzger, M., Haymann, J. P., Thervet, E., Boffa, J. J., et al. (2014) The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 9, e99781.
21. Troutt, J. S., Butterfield, A. M., and Konrad, R. J. (2013) Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J. Clin. Lab Anal. 27, 504–510.
22. Garrido, P., Ribeiro, S., Fernandes, J., Vala, H., Bronze-da-Rocha, E., et al. (2015) Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model. PLoS One 10, e0124048.
23. Fernandes, J. C., Garrido, P., Ribeiro, S., Rocha-Pereira, P., Bronze-da-Rocha, E., et al. (2014) Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia. Biomed. Res. Int. 2014, 421304.
24. Garrido, P., Ribeiro, S., Fernandes, J., Vala, H., Rocha-Pereira, P., et al. (2015) Resistance to recombinant human erythropoietin therapy in a rat model of chronic kidney disease associated anemia. Int. J. Mol. Sci. 17, E28.
25. Mastrogiannaki, M., Matak, P., Mathieu, J. R., Delga, S., Mayeux, P., et al. (2012) Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica 97, 827–834.
26. Maurer, E., Gutschow, M., and Stirnberg, M. (2012) Matriptase-2 (TMPRSS6) is directly up-regulated by hypoxia inducible factor-1: identification of a hypoxia-responsive element in the TMPRSS6 promoter region. Biol. Chem. 393, 535–540.
27. Hentze, M. W., Muckenthaler, M. U., Galy, B., and Camaschella, C. (2010) Two to tango: regulation of mammalian iron metabolism. Cell 142, 24–38.
28. Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S. H., Staker, P., et al. (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 13, 1096–1101.
29. Tanno, T., Porayette, P., Sripichai, O., Noh, S. J., Byrnes, C., et al. (2009) Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114, 181–186.
30. Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., et al. (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 46, 678–684.
31. Diaz, V., Gammella, E., Recalcati, S., Santambrogio, P., Naldi, A. M., et al. (2013) Liver iron modulates hepcidin expression during chronically elevated erythropoiesis in mice. Hepatology 58, 2122–2132.
32. Costa, E., Coimbra, J., Catarino, C., Ribeiro, S., Reis, F., et al. (2012) Major determinants of BMP-2 serum levels in hemodialysis patients. Renal Fail. 34, 1355–1358.
33. Meynard, D., Babitt, J. L., and Lin, H. Y. (2014) The liver: conductor of systemic iron balance. Blood 123, 168–176.
34. Chateauvieux, S., Grigorakaki, C., Morceau, F., Dicato, M., and Diederich, M. (2011) Erythropoietin, erythropoiesis and beyond. Biochem. Pharmacol. 82, 1291–1303.
35. Nairz, M., Sonnweber, T., Schroll, A., Theurl, I., and Weiss, G. (2012) The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect. 14, 238–246.
36. Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., et al. (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 75, 976–981.
37. Bailie, G. R., Larkina, M., Goodkin, D. A., Li, Y., Pisoni, R. L., et al. (2013) Variation in intravenous iron use internationally and over time: the dialysis outcomes and practice patterns study (DOPPS). Nephrol. Dial. Transplant. 28, 2570–2579.
38. Ribeiro, S., Belo, L., Reis, F., and Santos-Silva, A. (2016) Iron therapy in chronic kidney disease: recent changes, benefits and risks. Blood Rev. 30, 65–72.
39. Ferrari, P., Kulkarni, H., Dheda, S., Betti, S., Harrison, C., et al. (2011) Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 77–83.
40. Eleftheriadis, T., Liakopoulos, V., Antoniadi, G., Kartsios, C., and Stefanidis, I. (2009) The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial. 22, 70–77.